Nicole Assis Pereira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nicole Assis Pereira has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Leonardo José Richtzenhain
Departamento de Medicina Veterinária Preventiva, Faculdade de Medicina Veterinária e Zootecnia, Universidade de São Paulo, Av. Prof. Dr. Orlando Marques de Paiva, 87, São Paulo, 05508-270, Brazil
2 shared publicationsAntônio Carlos Alessi
Departamento de Patologia Veterinária, Faculdade de Ciências Agrárias e Veterinárias UNESP- Jaboticabal, Via de Acesso Prof. Paulo Donato Castellane, Jaboticabal, SP, 14884-900, Brazil
1 shared publication- Bianca de Carvalho Lins Fernandes Távora
Laboratory of Immunopathology Butantan Institute São Paulo Brazil
1 shared publication Bruno Rogério Rui
Departamento de Reprodução Animal, Universidade de São Paulo, Av. Prof. Dr. Orlando Marques de Paiva, 87, São Paulo, 05508-270, Brazil
1 shared publicationCatarina F.P. Teixeira
Laboratory of Pharmacology, Butantan Institute, Av. Vital Brasil 1500, 05503-900, São Paulo, SP, Brazil
1 shared publicationCésar Augusto Dinóla Pereira
Universidade de São Paulo, Instituto de Ciências Biomédicas, São Paulo, SP
1 shared publication
Latest Publications
- 17 December 2018
- Published by Springer Nature in Brazilian Journal of Microbiology
- Vol. 50 (1) , 313-320
Gonadal pathogenicity of an infectious bronchitis virus strain from the Massachusetts genotype
An outbreak of infectious bronchitis caused by the IBVPR03 strain of the Massachusetts genotype affected H-120 vaccinated laying hens in South Brazil. We investigated the cross protection of the vaccine by assessing the traqueal ciliostasis, virus recovery, and histopathological changes typically observed in the respiratory tract. Although the IBVPR03 strain is S1-genotyped as Massachusetts with a high genomic similarity to the H-120 vaccine strains, surprisingly, we found no tropism or pathogenicity to the trachea in birds infected with this strain. On the other hand, we observed ovarian and testicle lesions. Here, we show that, despite belonging in the Massachusetts genotype, the IBVPR03 pathotype differs from the expected respiratory pattern, causing instead marked histopathological changes in the gonads, so far not associated with this group.
- 17 December 2018
- Published by Springer Nature in Brazilian Journal of Microbiology
- Vol. 50 (1) , 313-320
Gonadal pathogenicity of an infectious bronchitis virus strain from the Massachusetts genotype
An outbreak of infectious bronchitis caused by the IBVPR03 strain of the Massachusetts genotype affected H-120 vaccinated laying hens in South Brazil. We investigated the cross protection of the vaccine by assessing the traqueal ciliostasis, virus recovery, and histopathological changes typically observed in the respiratory tract. Although the IBVPR03 strain is S1-genotyped as Massachusetts with a high genomic similarity to the H-120 vaccine strains, surprisingly, we found no tropism or pathogenicity to the trachea in birds infected with this strain. On the other hand, we observed ovarian and testicle lesions. Here, we show that, despite belonging in the Massachusetts genotype, the IBVPR03 pathotype differs from the expected respiratory pattern, causing instead marked histopathological changes in the gonads, so far not associated with this group.
- Open Access
- 27 May 2009
- Published by Wiley in Journal of Medical Virology
- Vol. 81 (7) , 1131-1139
Characterization of cytotoxic T‐lymphocyte epitopes and immune responses to SARS coronavirus spike DNA vaccine expressing the RGD‐integrin‐binding motif
Integrins are critical for initiating T‐cell activation events. The integrin‐binding motif Arg‐Gly‐Asp (RGD) was incorporated into the pcDNA 3.1 mammalian expression vector expressing the codon‐optimized extracellular domain of SARS coronavirus (SARS‐CoV) spike protein, and tested by immunizing C57BL/6 mice. Significant cell‐mediated immune responses were characterized by cytotoxic T‐lymphocyte 51Cr release assay and interferon‐gamma secretion ELISPOT assay against RMA‐S target cells presenting predicted MHC class I H2‐Kb epitopes, including those spanning residues 884–891 and 1116–1123 within the S2 subunit of SARS‐CoV spike protein. DNA vaccines incorporating the Spike‐RGD/His motif or the Spike‐His construct generated robust cell‐mediated immune responses. Moreover, the Spike‐His DNA vaccine construct generated a significant antibody response. Immunization with these DNA vaccine constructs elicited significant cellular and humoral immune responses. Additional T‐cell epitopes within the SARS‐CoV spike protein that may contribute to cell‐mediated immunity in vivo were also identified. J. Med. Virol. 81:1131–1139, 2009.
- 27 May 2009
- Published by Wiley in Journal of Medical Virology
- Vol. 81 (7) , 1131-1139
Open AccessCharacterization of cytotoxic T‐lymphocyte epitopes and immune responses to SARS coronavirus spike DNA vaccine expressing the RGD‐integrin‐binding motif
Integrins are critical for initiating T‐cell activation events. The integrin‐binding motif Arg‐Gly‐Asp (RGD) was incorporated into the pcDNA 3.1 mammalian expression vector expressing the codon‐optimized extracellular domain of SARS coronavirus (SARS‐CoV) spike protein, and tested by immunizing C57BL/6 mice. Significant cell‐mediated immune responses were characterized by cytotoxic T‐lymphocyte 51Cr release assay and interferon‐gamma secretion ELISPOT assay against RMA‐S target cells presenting predicted MHC class I H2‐Kb epitopes, including those spanning residues 884–891 and 1116–1123 within the S2 subunit of SARS‐CoV spike protein. DNA vaccines incorporating the Spike‐RGD/His motif or the Spike‐His construct generated robust cell‐mediated immune responses. Moreover, the Spike‐His DNA vaccine construct generated a significant antibody response. Immunization with these DNA vaccine constructs elicited significant cellular and humoral immune responses. Additional T‐cell epitopes within the SARS‐CoV spike protein that may contribute to cell‐mediated immunity in vivo were also identified. J. Med. Virol. 81:1131–1139, 2009.
- Open Access
- 1 October 2008
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Brazilian Journal of Veterinary Research and Animal Science
- Vol. 45 (5) , 385-389
Caracterização antigênica de isolados de parvovirus canino do Brasil utilizando monoclonais específicos
O Parvovírus Canino (CPV) é um patógeno emergente em cães, isolado pela primeira vez em 1978, nos Estados Unidos. A amostra original de 1978 foi designada CPV tipo 2 (CPV-2). Entretanto, análises de isolados de CPV dos Estados Unidos, por enzimas de restrição e anticorpos monoclonais demonstraram que cerca de 1979, uma amostra variante, designada CPV tipo 2a (CPV-2a) tornou-se prevalente. Subseqüentemente, uma nova amostra antigênica, designada CPV tipo 2b (CPV-2b) também foi observada por análises de isolados de CPV de várias partes do mundo, embora a proporção fosse diferente entre os países. Nesse estudo, foi utilizado o teste de Inibição da Hemaglutinação (HI) com um painel de anticorpos monoclonais para a tipagem de 29 amostras fecais de parvovirus canino, coletadas de cães sintomáticos de 1980 a 1986 e de 1990 a 1995. Os resultados indicaram uma forte predominância do tipo antigênico 2a indicando que a epizootia de CPV no Brasil seguiu o mesmo padrão observados na Europa e países Asiáticos.
- 1 October 2008
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Brazilian Journal of Veterinary Research and Animal Science
- Vol. 45 (5) , 385-389
Open AccessCaracterização antigênica de isolados de parvovirus canino do Brasil utilizando monoclonais específicos
O Parvovírus Canino (CPV) é um patógeno emergente em cães, isolado pela primeira vez em 1978, nos Estados Unidos. A amostra original de 1978 foi designada CPV tipo 2 (CPV-2). Entretanto, análises de isolados de CPV dos Estados Unidos, por enzimas de restrição e anticorpos monoclonais demonstraram que cerca de 1979, uma amostra variante, designada CPV tipo 2a (CPV-2a) tornou-se prevalente. Subseqüentemente, uma nova amostra antigênica, designada CPV tipo 2b (CPV-2b) também foi observada por análises de isolados de CPV de várias partes do mundo, embora a proporção fosse diferente entre os países. Nesse estudo, foi utilizado o teste de Inibição da Hemaglutinação (HI) com um painel de anticorpos monoclonais para a tipagem de 29 amostras fecais de parvovirus canino, coletadas de cães sintomáticos de 1980 a 1986 e de 1990 a 1995. Os resultados indicaram uma forte predominância do tipo antigênico 2a indicando que a epizootia de CPV no Brasil seguiu o mesmo padrão observados na Europa e países Asiáticos.